Bupropion is a reasonable treatment option for ADHD with comorbid dysthymia when stimulants are not accessible
Given the dual diagnosis of ADHD and dysthymia in this elderly patient who refuses stimulants due to access barriers, bupropion represents a pragmatic second-line choice that can address both conditions simultaneously.
Clinical Rationale
The evidence supports this approach through several mechanisms:
For ADHD treatment specifically:
- Bupropion has been reported anecdotally as beneficial for adult ADHD 1
- Guidelines explicitly state bupropion and tricyclics are "second-line agents, at best, for treating ADHD" 1
- Recent systematic reviews found low-quality evidence that bupropion decreased ADHD symptom severity (standardized mean difference -0.50) and increased clinical improvement rates (RR 1.50) compared to placebo 2
- Meta-analysis showed bupropion superior to placebo with weighted mean difference of 5.08 points on ADHD rating scales 3
For dysthymia treatment:
- Bupropion has proven antidepressant activity in adults 1
- FDA-approved for major depressive disorder at 300 mg daily 4
- Guidelines recommend bupropion as a treatment option for depression in elderly patients 5
- The drug is "activating" which may help with energy levels and apathy 6
Practical Implementation
Dosing strategy:
- Start with 37.5 mg every morning, then increase by 37.5 mg every 3 days 6
- Target dose: 150 mg twice daily (maximum for ADHD/depression) 6
- Give second dose before 3 PM to minimize insomnia risk 6
- In elderly patients with renal impairment (common in this age group), consider reduced dosing frequency 7
Critical Safety Considerations
Seizure risk is the primary concern:
- Bupropion lowers seizure threshold 4
- Avoid in patients with seizure disorders 6
- Risk increases with doses above 450 mg/day
- Do not exceed 150 mg per single dose
Monitoring requirements:
- Blood pressure and pulse (can cause increases) 4
- Suicidality monitoring, especially in patients under 24 years (though less relevant here) 4
- Clinical worsening of depression 8
- Renal function in elderly patients 7
Important Caveats
Limitations of this approach:
- Bupropion's efficacy for ADHD is substantially less than stimulants 8
- Evidence quality is low with small sample sizes 2
- 6-12 weeks may be needed to observe full effects on mood, though ADHD effects may appear sooner
- No data support a single antidepressant definitively treating both ADHD and depression simultaneously 1
Alternative considerations if bupropion fails:
- Atomoxetine (non-stimulant ADHD medication with 6-12 week onset) 8
- Alpha-2 agonists (guanfacine, clonidine) for ADHD 8
- Separate antidepressant (SSRI) plus addressing stimulant access barriers
- Tricyclics (nortriptyline, desipramine) though higher anticholinergic burden in elderly 6
The reality of stimulant access: While bupropion is reasonable given the circumstances, the patient's access barrier to stimulants represents a systems-level problem that ideally should be addressed, as stimulants remain first-line therapy with superior efficacy 8. Consider exploring mail-order pharmacies, different stimulant formulations with better availability, or advocacy for improved access.